Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp vs BIAsp 30 in Type 2 Diabetes (BOOST: INTENSIFY PREMIX/ALL 2)
NCT02762578Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started May 2016; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02762578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762578.